Scienture Holdings, Inc. (SCNX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 17 | 10 | 10 | 1 | 0 | 0 | 1 | - |
| Operating profit | $m | -16 | -14 | ||||||
| Net profit | $m | -3 | -5 | -3 | -18 | 9 | -42 | -38 | -35 |
| EPS reported | $ | -2.70 | -2.04 | ||||||
| Operating cashflow per share | $ | -0.09 | -153.0 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.09 | -153.0 | ||||||
| Free cash flow | $m | -13,382 | -14 | ||||||
| Net debt | $m | -7 | 2 | ||||||
| Book value equity | $m | 70 | 64 | ||||||
| Book value per share | $ | 0.46 | 1.62 | ||||||
| Number of shares | m | 153.47 | 39.62 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.12 | 1.22 | ||||||
| P/S LTM | x | 181.35 | 95.30 | ||||||
| P/FCF LTM | x | -0.01 | -5.42 | ||||||
| EV/EBITDA LTM | x | -1.84 | -1.98 | ||||||
| EV/Sales LTM | x | 165.97 | 3,065.14 | ||||||
| Earnings Yield LTM | % | -53.04% | -2.09% | ||||||
| FCF Yield | % | -17097.6% | -18.45% | ||||||
| Quality | |||||||||
| ROE | % | -59.20% | -0.12% | ||||||
| ROIC | % | -19.03% | -0.02% | ||||||
| Operating margin | % | -37.64% | -16.71% | ||||||
| Gross margin | % | +76.80% | +30.73% | ||||||
| FCF/Sales | % | -3100.0% | -737839.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +215.87% | +501.07% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -554,438.50 | -1.35 | ||||||
| Net Debt/EBITDA | x | 0.17 | -69.22 | ||||||
| EBIT/Net interest | x | -3.98 | -4.48 | ||||||
| Net debt/market cap | % | 0.00% | +573.18% | ||||||
| Net debt/Equity | x | -0.10 | 0.04 | ||||||
| Gross debt/equity | x | 0.00 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free